Results 11 to 20 of about 121,038 (379)
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
European Journal of Heart Failure, 2022 It remains unknown whether the consistently observed increase in haematocrit with sodium–glucose cotransporter 2 inhibitors is caused by diuresis‐associated haemoconcentration or increased erythropoiesis.
Camilla Fuchs Andersen +15 more
semanticscholar +1 more source
Erythropoiesis and Malaria, a Multifaceted Interplay
International Journal of Molecular Sciences, 2022 One of the major pathophysiologies of malaria is the development of anemia. Although hemolysis and splenic clearance are well described as causes of malarial anemia, abnormal erythropoiesis has been observed in malaria patients and may contribute ...
Aurélie Dumarchey +2 more
semanticscholar +1 more source
American Journal of Nephrology, 2021 Background: Patients with CKD frequently have anemia that results from iron-restricted erythropoiesis and inflammation. Anemia of CKD is currently managed with iron supplements and erythropoiesis-stimulating agents (ESAs) to promote erythropoiesis and ...
M. Weir
semanticscholar +1 more source
Molecular and cellular mechanisms that regulate human erythropoiesis
Blood, 2021 Edited by Associate Editor Mario Cazzola, this review series highlights 3 specific areas of scientific and clinical advances in understanding disorders of red cell production.
A. Caulier, V. Sankaran
semanticscholar +1 more source
Ineffective erythropoiesis and its treatment.
Blood, 2021 The erythroid marrow and circulating red blood cells (RBCs) are the key components of the human erythron. Abnormalities of the erythron that are responsible for anemia can be distinguished into 3 major categories, that is, erythroid hypoproliferation ...
M. Cazzola
semanticscholar +1 more source
Development of luspatercept to treat ineffective erythropoiesis.
Blood Advances, 2021 Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS) and/or SF3B1 mutation who were not eligible for erythropoiesis-stimulating agents (ESAs ...
A. Kubasch, P. Fenaux, U. Platzbecker
semanticscholar +1 more source
Frontiers in Cell and Developmental Biology, 2021 Erythroblastic islands (EBIs), discovered more than 60 years ago, are specialized microenvironments for erythropoiesis. This island consists of a central macrophage with surrounding developing erythroid cells.
Wei Li +3 more
semanticscholar +1 more source
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Journal of Clinical Endocrinology and Metabolism, 2020 CONTEXT Dapagliflozin and other SGLT2 inhibitors are known to increase hematocrit possibly due to it diuretic effects and hemoconcentration. OBJECTIVE Since type 2 diabetes is a pro-inflammatory state and since hepcidin, a known suppressor of ...
H. Ghanim +7 more
semanticscholar +1 more source
American journal of hematology/oncology, 2021 Identification of stage‐specific erythroid cells is critical for studies of normal and disordered human erythropoiesis. While immunophenotypic strategies have previously been developed to identify cells at each stage of terminal erythroid differentiation,
Hongxia Yan +13 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2021 Erythropoiesis regulation is essential in normal physiology and pathology, particularly in myelodysplastic syndromes (MDS) and β-thalassemia. Several signaling transduction processes, including those regulated by inositides, are implicated in ...
S. Parisi +10 more
semanticscholar +1 more source